Cost-effectiveness of an urinary biomarker panel in combination with MRI for prostate cancer diagnosis.

Tim M GoversMatthew J ResnickArdeshir R RastinehadLaura CabaJack GroskopfWim van Criekinge

Published in: World journal of urology (2023)

Application of SelectMDx results in better health outcomes and cost savings. The value of SelectMDx was highest when used before MRI to select patients for MRI and subsequent biopsy.

Keyphrases

contrast enhanced
prostate cancer
magnetic resonance imaging
diffusion weighted imaging
end stage renal disease
newly diagnosed
ejection fraction
computed tomography
prognostic factors
ultrasound guided
peritoneal dialysis
fine needle aspiration